RENAL OUTCOMES IN DIABETIC KIDNEY PATIENTS TREATED WITH GLP1 AGONIST RECEPTORS VS SGLT2 INHIBITORS

被引：0
|
作者：
Maroto, Alba [1 ]
Vidas, Maria Marques [1 ]
Sanz, Ignacio [1 ]
Lopez, Paula [1 ]
Portoles, Jose' M. [1 ]
机构：
[1] Hosp Univ Puerta Hierro Majadahonda Madrid, Nephrol, Majadahonda, Spain
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
P1009
引用
下载
收藏
页码：1331 / 1331
页数：1
相关论文
共 50 条
  • [31] Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
    Kelly, Michael S.
    Lewis, Jelena
    Huntsberry, Ashley M.
    Dea, Lauren
    Portillo, Ivan
    POSTGRADUATE MEDICINE, 2019, 131 (01) : 31 - 42
  • [32] Type 2 Diabetes Mellitus: GLP1 Receptor Agonists and SGLT2 Inhibitors in Patients Referred to Ambulatory Consultant Cardiology Clinics
    Antonelli, Dante
    Rabkin, Youri
    Turgeman, Yoav
    Jabaren, Mohamed
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2023, 25 (02): : 143 - 146
  • [33] SGLT2 inhibitors and kidney outcomes in the real world
    Smith, Steven M.
    BMJ-BRITISH MEDICAL JOURNAL, 2020, 369
  • [34] COMPARATIVE EFFECTIVENESS OF SGLT2 INHIBITORS VERSUS GLP1 AGONISTS ON PREVENTING POST-TRAUMATIC OSTEOARTHRITIS
    Jafarzadeh, S. Reza
    Peloquin, Christine E.
    Felson, David
    OSTEOARTHRITIS AND CARTILAGE, 2024, 32 : S595 - S595
  • [35] Acceptance of Recommendations for SGLT2 Inhibitors and GLP1 Receptor Agonists in a High-Risk CKD Population
    Weltman, Melanie R.
    Jhamb, Manisha
    Yabes, Jonathan
    Cai, Manqi
    Nolin, Thomas D.
    Abdel-Kader, Khaled
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 865 - 865
  • [36] Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
    Winiarska, Agata
    Knysak, Monika
    Nabrdalik, Katarzyna
    Gumprecht, Janusz
    Stompor, Tomasz
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (19)
  • [37] GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-world Clinical Practice
    Diaz-Trastoy, Olaia
    Villar-Taibo, Rocio
    Sifontes-Dubon, Mildred
    Mozo-Penalver, Hector
    Bernabeu-Moron, Ignacio
    Cabezas-Agricola, Jose M.
    Munoz-Leira, Virginia
    Peino-Garcia, Roberto
    Martis-Sueiro, Aurelio
    Garcia-Lopez, Jose M.
    Martinez-Olmos, Miguel A.
    CLINICAL THERAPEUTICS, 2020, 42 (02) : E1 - E12
  • [38] Real-world evaluation of insulin requirements after GLP1 agonist or SGLT2 inhibitor initiation and titration
    George, Jamie
    Lobkovich, Alison
    Nardolillo, Joseph
    Farhat, Nada
    Kolander, Sarah
    Thomas, Emily
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (14) : 1151 - 1157
  • [39] Cardiovascular outcomes in patients with type 2 diabetes who added either GLP1 receptor agonists or DPP4 inhibitors to SGLT2 inhibitor therapy
    Bykov, Katsiaryna
    Kim, Seoyoung
    Dave, Chintan
    Levin, Raisa
    Wexler, Deborah
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 98 - 98
  • [40] Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital
    Labrini Papanastasiou
    Spyridoula Glycofridi
    Christos Gravvanis
    Nikitas Skarakis
    Irene Papadimitriou
    Georgia Kanti
    Chara Kapsali
    Theodora Kounadi
    Hormones, 2021, 20 : 369 - 376
12345